Evidence map›Paper›PMID 32752075›Full record

ArticlePharmaceuticals (Basel, Switzerland)2020

Automated GMP-Compliant Production of [

Michael Wagner, Johan G Doverfjord, Joachim Tillner, Gunnar Antoni, Torsten Haack, Martin Bossart, Iina Laitinen, Lars Johansson, Stefan Pierrou, Olof Eriksson and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Towards Optimal AutomatedJournal of labelled compounds & radiopharmaceuticals · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Michael WagnerR&D Research Platform, Integrated Drug Discovery, Sanofi, 65929 Frankfurt, Germany.
Johan G DoverfjordPET Center, Center for Medical Imaging, Uppsala University Hospital, 751 85 Uppsala, Sweden.
Joachim TillnerTranslational Medicine, Sanofi, 65929 Frankfurt, Germany.ORCID 0000-0002-2798-2732
Gunnar AntoniDepartment of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.
Torsten HaackR&D Research Platform, Integrated Drug Discovery, Sanofi, 65929 Frankfurt, Germany.
Martin BossartR&D Research Platform, Integrated Drug Discovery, Sanofi, 65929 Frankfurt, Germany.
Iina LaitinenGlobal Imaging, Sanofi, 65929 Frankfurt, Germany.
Lars JohanssonAntaros Medical AB, 431 83 Mölndal, Sweden.
Stefan PierrouAntaros Medical AB, 431 83 Mölndal, Sweden.
Olof ErikssonAntaros Medical AB, 431 83 Mölndal, Sweden.
Irina VelikyanScience for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.ORCID 0000-0002-3732-8857
Sanofi (Germany) · DEUppsala University · SEAntaros Medical (Sweden) · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

automationdiabetesGallium-68glucagon receptorGMPradiopharmaceuticals

Identifiers

PMID32752075
PMCPMC7463542
OpenAlexW3046756819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.